As clinical drug development becomes more complex and resource-intensive, the FDA’s recent draft guidance on the use of Bayesian statistical methods in clinical trials signals a move toward more ...
Industry groups and drugmakers want the US Food and Drug Administration (FDA) to explicitly clarify that Bayesian statistical methods can be used for products beyond those intended for children and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results